CA
NZ
UK
AU
IND
US
…
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public disclosures for enGene Holdings Inc. are limited; the company describes itself as a clinical-stage biotechnology firm developing targeted nucleic-acid delivery therapies. Long-term growth may depend on advancing clinical programs, securing partnerships and regulatory approvals, which could support program value and may attract investors seeking exposure to novel therapeutic delivery approaches.
Key investment risks include clinical and regulatory failure, high cash burn and the need for external financing with dilution risk, limited operating history and liquidity, and competitive and execution uncertainty.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -99.90M | -24.44M | -23.44M | -15.07M |
| Net income | -99.92M | -24.46M | -23.44M | -15.07M |
| Selling general administrative | 8.47M | 3.26M | 3.15M | 3.24M |
| Reconciled depreciation | 0.17M | 0.24M | 0.27M | 0.26M |
| Ebit | - | -19.69M | -15.97M | -13.16M |
| Ebitda | - | -19.45M | -15.70M | -12.90M |
| Depreciation and amortization | - | 0.24M | 0.27M | 0.26M |
| Operating income | -26.06M | -19.43M | -15.87M | -13.85M |
| Other operating expenses | - | 19.43M | 15.87M | 13.85M |
| Interest expense | 4.95M | 1.42M | 5.02M | 3.70M |
| Tax provision | 0.02M | 0.02M | 0.00M | 0.00M |
| Interest income | 1.12M | 0.13M | 0.03M | 0.06M |
| Net interest income | -3.84M | -1.29M | -5.00M | -3.64M |
| Income tax expense | - | 0.02M | 4.90M | 4.33M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 26.06M | 19.43M | 15.87M | 13.85M |
| Total other income expense net | -70.00M | -3.72M | -2.57M | 2.43M |
| Net income from continuing ops | -99.92M | -24.46M | -23.44M | -15.07M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 86.96M | 23.91M | 15.03M |
| Other current assets | 1.50M | 0.74M | 0.80M |
| Total liab | 14.47M | 100.52M | 68.47M |
| Total stockholder equity | 72.49M | -76.61M | -53.44M |
| Other current liab | 0.22M | 3.12M | 0.02M |
| Common stock | 259.37M | 16.39M | 16.36M |
| Capital stock | 259.37M | 16.39M | 16.36M |
| Retained earnings | -199.59M | -99.67M | -75.21M |
| Cash | 81.52M | 20.43M | 11.02M |
| Total current liabilities | 5.26M | 5.10M | 3.22M |
| Current deferred revenue | 3.32M | - | 1.08M |
| Net debt | -71.74M | 11.68M | -6.86M |
| Short term debt | 0.56M | 1.26M | 1.11M |
| Short long term debt | 0.56M | 1.26M | 1.05M |
| Short long term debt total | 9.78M | 32.11M | 4.16M |
| Other stockholder equity | 13.72M | -45.44M | -45.53M |
| Total current assets | 85.44M | 22.58M | 13.52M |
| Net receivables | 2.34M | 1.34M | 1.62M |
| Long term debt | 9.22M | 30.84M | 3.05M |
| Inventory | 0.08M | 0.07M | 0.08M |
| Accounts payable | 1.16M | 0.72M | 1.00M |
| Accumulated other comprehensive income | -1.02M | -1.02M | -2.18M |
| Non currrent assets other | 0.93M | 0.94M | 0.94M |
| Non current assets total | 1.52M | 1.33M | 1.51M |
| Capital lease obligations | - | 0.00M | 0.06M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -0.32M | -0.15M | -0.25M | -0.19M |
| Total cash from financing activities | 86.15M | 27.97M | 22.52M | 12.85M |
| Net income | -99.92M | -24.46M | -23.44M | -15.07M |
| Change in cash | 61.09M | 9.42M | 6.39M | -0.46M |
| Begin period cash flow | 20.43M | 11.02M | 4.62M | 5.08M |
| End period cash flow | 81.52M | 20.43M | 11.02M | 4.62M |
| Total cash from operating activities | -24.74M | -17.59M | -15.98M | -13.06M |
| Issuance of capital stock | 56.89M | 0.01M | 15.60M | 0.00M |
| Depreciation | 0.17M | 0.24M | 0.27M | 0.26M |
| Other cashflows from financing activities | 33.99M | 28.96M | 23.48M | 12.85M |
| Capital expenditures | 0.32M | 0.15M | 0.25M | 0.19M |
| Change in working capital | -0.52M | 2.17M | -1.04M | 0.39M |
| Stock based compensation | 3.45M | 0.12M | 0.43M | 0.15M |
| Other non cash items | 79.33M | 0.37M | 4.97M | 2.99M |
| Free cash flow | -25.06M | -17.75M | -16.23M | -13.25M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| ENGN enGene Holdings Inc. Common Stock |
0.17 11.72% |
1.62 | - | - | - | 9.09 | -6.01 |
| NVO Novo Nordisk A/S |
-0.24 0.61% |
40.20 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-21.28 3.85% |
531.87 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
12.10 1.26% |
973.36 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
7171 Rue Frederick Banting, Saint-Laurent, QC, Canada, H4S 1Z9
514 332 4888
31
| Name | Title | Year Born |
|---|---|---|
| Mr. Jason D. Hanson Esq., J.D. | CEO & Director | 1969 |
| Dr. Alex Nichols Ph.D. | President & COO | 1986 |
| Dr. James C. Sullivan M.Sc., Ph.D. | Chief Scientific Officer | 1979 |
| Dr. Anthony T. Cheung Ph.D. | Co-Founder & CTO | 1972 |
| Mr. John C. Brown D.Sc., FRSC, Ph.D. | Co-Founder and Member of Scientific Advisory Board | NA |
| Mr. David Ryan Daws | CFO & Head of Business Development | 1974 |
| Mr. Lee G. Giguere | Chief Legal Officer & Corporate Secretary | 1981 |
| Ms. Sharon Tan | VP of Project Management & Head of Program Management | NA |
| Dr. Richard P. Bryce MBChB, MFPM, MRCGP | Chief Medical Officer | 1957 |
| Mr. Paul Erickson | Non-Executive Director | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.39%
Communication Services
+0.40%
Consumer Cyclical
-0.20%
Consumer Defensive
-0.56%
Energy
-0.45%
Financial Services
-0.09%
Financials
+0.11%
Healthcare
+0.40%
Industrials
+0.34%
Real Estate
-0.14%
Technology
+0.88%
Utilities
+0.11%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...